Arch Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Arch Therapeutics's estimated annual revenue is currently $1.7M per year.
- Arch Therapeutics's estimated revenue per employee is $113,667
- Arch Therapeutics's total funding is $20.9M.
Employee Data
- Arch Therapeutics has 15 Employees.
- Arch Therapeutics grew their employee count by 25% last year.
Arch Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman the Board Directors, President & CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | VP Sales | Reveal Email/Phone |
4 | Associate Director, Clinical Operations | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Project Manager | Reveal Email/Phone |
7 | Executive Assistant | Reveal Email/Phone |
8 | Sales Director | Reveal Email/Phone |
9 | Staff Design Quality Engineer | Reveal Email/Phone |
Arch Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Arch Therapeutics?
Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V® and AC5® Surgical Hemostat, among others.1,2 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use. 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.
keywords:N/A
$20.9M
Total Funding
15
Number of Employees
$1.7M
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Arch Therapeutics News
FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (Arch or the Company), a marketer and...
(OTCQB: ARTH) (Arch or the Company), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced...
FRAMINGHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (Arch or the Company), a marketer and...
Other Companies in Framingham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.3M | 15 | 67% | N/A |
#2 | $1.3M | 15 | 0% | N/A |
#3 | $1.3M | 15 | -6% | N/A |
#4 | $2.3M | 15 | -12% | N/A |
#5 | $0.5M | 16 | -27% | $3.9M |